Nada Elbuluk, MD, MSc, FAAD

Articles by Nada Elbuluk, MD, MSc, FAAD

Future Initiatives by the Skin of Color Society in Dermatology, with Nada Elbuluk, MD, MSc

March 9th 2025

This interview at the Skin of Color Society (SOCS) Scientific Symposium features Elbuluk describing her plans as newly-elected president of SOCS.

Key Takeaways on Vitiligo Management

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 24th 2023

Expert dermatologists share final thoughts on treatment of vitiligo and topical ruxolitinib.

Promoting Access to New Therapies in Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 24th 2023

Experts in dermatology comment on the need to promote access to emerging treatments in vitiligo.

Managing Vitiligo Patient Expectations

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 24th 2023

Heather Woolery-Lloyd, MD, and Nada Elbuluk, MD, share approaches to patient education and managing patient expectations when repigmenting the skin in vitiligo.

Disease Burden for Patients With Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 17th 2023

Expert dermatologists discuss the impact of vitiligo and vitiligo treatment on quality of life.

Treatment Response to Conventional vs Emerging Therapies in Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 17th 2023

Nada Elbuluk, MD, and Ted Lain, MD, compare response to conventional treatment options vs emerging therapies, such as ruxolitinib, in the treatment of vitiligo.

Treatment Approaches to Ruxolitinib in Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 10th 2023

Experts in dermatology share their impressions of ruxolitinib and approaches to vitiligo treatment in clinical practice.

Adverse Events of Ruxolitinib in Vitiligo Trials

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 10th 2023

Heather Woolery-Lloyd, MD, discusses the adverse event profile of topical ruxolitinib for treatment of vitiligo, highlighting the well-tolerated nature of the drug.

Impact of UV Light Exposure on Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 3rd 2023

Expert dermatologists comment on the impact of UV light exposure on areas of the skin with vitiligo and their recommendations for sunscreen use.

Use of Ruxolitinib for Treatment of Vitiligo

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

May 3rd 2023

Experts in dermatology review the mechanism of action and clinical trials of topical ruxolitinib for repigmenting the skin in vitiligo.

Measuring Vitiligo Treatment Response

BySeemal R. Desai, MD,Heather Woolery-Lloyd, MD,Brittany G. Craiglow, MD,Nada Elbuluk, MD, MSc, FAAD,Ted Lain, MD

April 26th 2023

Brittany Craiglow, MD, discusses the lengthy nature of vitiligo treatment response and how to approach communicating with patients who want to see change quickly.